Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DXJH93
|
|||
| Drug Name |
AK104
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Cervical cancer [ICD-11: 2C77.0; ICD-9: 180] | Phase 2 | [1] | |
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 2 | [2] | ||
| Company |
Akeso Biopharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytotoxic T-lymphocyte protein 4 (CTLA-4) | Target Info | Inhibitor | [3] |
| Programmed cell death protein 1 (PD-1) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Autoimmune thyroid disease | ||||
| Rheumatoid arthritis | ||||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| Reactome | CTLA4 inhibitory signaling | |||
| PD-1 signaling | ||||
| WikiPathways | Vitamin D Receptor Pathway | |||
| T-Cell Receptor and Co-stimulatory Signaling | ||||
| Allograft Rejection | ||||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04380805) A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04728321) A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Akeso Biopharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.